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 The Interferon (IFN) receptor-mediated signal transduction 
pathways involve the two novel DNA-binding factors, inter-
feron regulatory factor-1 (IRF-1) and IRF-2. Both recognize 
the same DNA sequence, in which the expression ratio of 
IRF-1 to IRF-2 is relevant to induction of IFN-inducible genes, 
because IRF-1 acts as a transcriptional activator and IRF-2 
as a counterpart. In the present study, 54 patients with 
chronic hepatitis C and the age-and sex-matched 7 subjects 
with fatty liver as a control were subjected to analysis of 
the expression ratio of IRF-1 to IRF-2 mRNA in the liver tis-
sue obtained at the time of livert biopsy by reverse 
transcription-polymerase chain reaction in combination with a 
restriction fragment length polymorphism assay. The expres-
sion ratio of IRF-1 to IRF-2 mRNA in the liver tissue in pa-
tients chronically infected by hepatitis C virus (HCV) was 
significantly higher than that in control, although the val-
ues did not correlate with the serum levels of HCV-RNA. Of 
54 patients, 28 received IFN treatment, resulting in complete 
response in 8 patients. With respect to responsiveness to IFN 
treatment, patients who had complete response had the rela-
tively lower ratios of IRF-1 to IRF-2 mRNA in the liver tis-
sue, compared with those who did not. These results indicate 
that the IFN-mediated pathway is spontaneously activated in 
patients with chronic hepatitis C, and that its preceded 
overactivation counteracts on the efficacy of IFN treatment 
in these patients.
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Introduction
 Interferon (IFN) treatment succeeds in viral eradica-
tion in 20-30% of patients chronically infected by 
hepatitis C virus (HCV) 1-4). Its efficacy is closely asso-
ciated with low levels of viremia or mutations in the 
HCV-RNA sequence, especially in the NS5A region". 
However, the relationship between antiviral states against 
HCV and response to IFN is stil unclear. Recent ad-
vances in molecular biology lead to a great deal of 
progress in host-defense mechanisms against viral in-
fections. In the IFN system, both interferon regulatory 
factor-1 (IRF-1) and IRF-2 genes are induced by viral in-
fections or by IFNs or, to some degrees, other cytokines 
7-1o) Both gene products act as the transcriptional factors 
which recognize the same DNA sequence. However, since 
IRF-1 functions as a transcriptional activator and IRF-2 
as a counterpart, the expression ratio-of IRF-1 to IRF-2 is 
relevant to induction of IFN-inducible gene expression". 
In the present study, the expression ratios of IRF-1 to 
IRF-2 mRNA in the liver tissue were analyzed in pa-
tients with chronic hepatitis C.
Patients and Methods
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Patients population 
 The sample population included 54 patients chroni-
cally infected by HCV who were admitted to our hospital
between 1994 and 1995; 39 were men and 15 were women, 
and they were 24 to 75 years of age (mean [ ± SD], 50 
± 13). The 54 patients were positive for HCV-RNA by 
reverse transcription-polymerase chain reaction (RT-
PCR) and antibody to HCV, but negative for hepatitis 
B surface antigen. Informed consent was obtained from 
all patients. Liver biopsies were performed, and the diag-
nosis of chronic hepatitis was made on the basis of the 
histological findings in liver tissue in all patients. The 
serum levels of HCV-RNA were determined by a 
branched DNA (bDNA) assay. We also studied the 
age-and sex-matched 7 subjects with fatty liver who 
were admitted to our hospital during the same period 
and gave informed consent. There were 5 men and 2 
women, aged 36 to 61 years (mean [ ± SD], 50 ± 10). 
The 7 control subjects were negative for any viral 
markers tested or autoantibodies to nuclear antigens 
or mitochondrial antigens. Any of alcohol or drug 
abusers were excluded from the study.
IFN treatment 
 IFN treatment was performed in 28 of 54 patients with 
chronic hepatitis C. The 28 patients received IFN- a for 
6 months in a dose of 6 million to 9 million units intra-
muscularly everyday for 14 days and then three times 
a week for 22 wk (total dose, 480 million to 720 million 
units). All patients were followed, and those who per-
sisted to become negative for HCV-RNA by RT-PCR 
together with normalization of liver function tests for 
more than 1 year after cessation of IFN treatment 
were defined as complete responders as described pre-
viously6>. According to the definition, 8 of 28 patients 
had complete response, whereas 20 had no response be-
cause they persisted or returned to be positive for 
HCV-RNA during the follow-up period.
Analysis of expression ratio of IRF-1 to IRF-2 mRNA in 
liver tissue 
 The liver tissue specimens obtained at the time of liver 
biopsy were frozen at -70°C immediately after the time 
of liver biopsy for later analysis of the expression 
ratio of IRF-1 to IRF-2 mRNA in the liver tissue by RT-
PCR in combination with a restriction fragment length 
polymorhism assay","'. Total cellular RNA was iso-
lated from the frozen samples by the guanitidium 
isothiocyanate method. Two p g of total RNA in a vol-
ume of 10 p 1 was heated at 68°C for 3 min, chilled on 
ice, then added in a reaction mixture containing 50,u M 
Tris-HC1 (pH8.3), 75mM KCI, 3mM MgCl2, 200p M each 
of dNTPs, 100pmol random hexamer, 8U of RNase in-
hibitor, and 200U of M-MLV reverse transcriptase to a
volume of 20,u 1. The RT reaction mixture was incu-
bated at 37C for 90 min, heated at 95C for 5min, and 
chilled on ice. The two pairs of oligonuleotide primers, 
by which IRF-1 and IRF-2 DNA sequences having a 
relatively higher homology'' (nucleotide 302-508 and 
nucleotide 162-368, respectively) were amplified in the 
same length (207bp) and only the IRF-2 sequence was 
digested by a restriction enzyme, Nsi-I (which recog-
nizes ATGC A/T), resulting in 155bp and 52bp frag-
ments, were used in this study as follows: for IRF-1, 5'-
CCGGGGCTCATCTGGATTAA-3' and 5'-ATCTGGCAGG-
GAGTTCATGG-3', and for IRF-2, 5'-CCGGGGCTCAAG-
TGGCTTAA-3' and 5-ATCAGGCAAGGAATTCATGG-3'. 
Briefly, the PCR was performed in a reaction volume 
of 50 p 1 containing 2 p 1 of the RT reaction product, 
50mM KCI, 10mM Tris (pH9.0 ), 1.5mM MgCl2, 0.1% 
Triton X-100, 200,u M each of dNTPs, 25pmol each of 
PCR primers and 2.51U of Taq DNA polymerase. The 
amplification was performed by 25 cycles in a pro-
grammable DNA thermal cycler. Each reaction cycle 
involved denaturation at 92C for 30 sec, primer an-
nealing at 60°C for 30 sec and primer extension at 72°C 
for 1 min. In the last cycle, the reaction at 72 °C con-
tinued for 10 min to ensure complete DNA extension. 
The PCR product was extracted, with phenol-chloroform 
and precipitated with ethanol. The precipitated prod-
uct was digested by 5IU of Nsi-I at 37 °C for 2hr, and 
the digested product was separated by electrophoresis 
on a2% agalose gel. The separated bands correspond-
ing to IRF-1 and IRF-2 DNA fragments were visualized 
with etidium bromide staining. The intensity of each 
band was quantified by densitometry with a image 
program from Macintosh 131. When IRF-1 cDNA and 
IRF-2 cDNA (generous gifts from professor T.Taniguchi, 
Tokyo University, Japan) were mixed to yield differ-
ent ratios and the mixed samples were subjected to 
the same analysis, the ratio of IRF-1 to IRF-2 deter-
mined by this method closely correlated with that in 
the mixed sample prepared before analysis (Figure 1). 
Accordingly, each assay always contained the prepared 
DNA samples with the different ratios of IRF-1 to IRF-
2 to make a standard curve, and the expression ratio 
of IRF-1 to IRF-2 in each liver tissue sample was calcu-
lated from the standard curve. 
 The statistical analyses were performed with Student's 
t-test and the chi-square test. All P values were two-
tailed, and P values of less than 0.05 were considered 
to indicate statistical significance.
Figure 1. Correlation between the ratios of IRF-1 to IRF-2 
determined by our method and those expected before analy-
sis. IRF-1 cDNA and IRF-2 cDNA were mixed to obtain the 
indicated ratios. The prepared samples were subjected to 
analysis as described in Methods.
Figure 3. Correlation between the expression ratio of IRF-1 
to IRF-2 mRNA in the liver tissue and the serum level of 
HCV-RNA in patients with chronic hepatitis C. The HCV-
RNA level was assayed using a branched DNA assay, and its 
detection limit was 0.5 megaequivalent per milliliter (Meq/ml ).
chronic hepatitis C than in control (mean [±SD], 2.48 
± 1.97 vs. 0.63 ± 0.34, P<0.01), although the ratios in 
patients ranged widely from 0.57to 12.3 (Figure 2). The 
serum levels of HCV-RNA were determined by a branched 
DNA (bDNA) assay. Among 54 patients, the values were 
less than 0.5 Meq/ml (a detection limit) in 15 patients 
and ranged from 0.6 to 126 Meq/ml in 39 patients. When 
the expression ratios of IRF-1 to IRF-2 mRNA in the 
liver tissue were compared with the serum levels of HCV-
RNA in the 54 patients, no correlation was observed 
(Figure 3).
Figure 2. Hepatic expression ratios of IRF-1 to IRF-2 mRNA 
in patients with chronic hepatitis C and those with fatty 
liver. The expression ratios were determined in 54 patients 
with chronic hepatitis C and 7 patients with fatty liver as a 
control as described in Methods. Bars are means±SD.
Results
Elevated expression ratio of IRF-1 to IRF-2 mRNA in the 
liver tissue in patients with chronic hepatitis C 
 The expression . ratio of IRF-1 to IRF-2 mRNA in the 
liver tissue was significantly higher in patients with
 Analysis of factors involved in response to IFN in pa-
tients with chronic hepatitis C 
 Twenty-eight of 54 patients received IFN treatment. 
Of 28 patients, 8 had complete response, because these 
patients persisted to become negative for HCV-RNA 
together with normalization of liver function tests for 
more than 1 year after cessation of IFN treatment. The 
age or sex did not correlate with outcome of IFN 
treatment (Table 1). However, sustained response to 
IFN was observed more frequently in patients who 
had relatively low levels of HCV-RNA with less than 
l Meq/ml at baseline, compared with those who did not 
(P<0.01). To evaluate the correlation between the ex-
pression ratio of IRF-1 to IRF-2 mRNA in the liver tis-
sue and response to IFN, the cutoff value for the ratio 
was set at 2.5, which was the mean value in the 54 pa-
tients chronically infected by HCV. Seven (47%) of 15 
patients who had the ratios of less than 2.5 resulted in 
complete response, whereas only 1 (8%) of 13 patients 
who had the ratios of 2.5 or more did. The difference was
statistically significant (P< 0.05). Moreover, when the 
ratio was combined with the baseline serum level of 
HCV-RNA for an index of response to IFN, 6 (86%) of 
7 patients who had both the ratio of less than 2.5 and the 
aseline HCV-RNA level of less than 1Meq/ml resulted in 
complete response, whereas only 2 (10%) of 21 patients 
who did not had complete response (P< 0.001).
Table 1 Factors invoived in respones to interferon in 28 pa-
tients
       Variable No. of No. of x2 
                           patients complete responders (%) 
Age 
 <50yr. 19 5(26%) 
                                                          p=0.7011
 a50yr. 9 3(33%) 
Sex 
 Male 19 6(32%) 
                                                          p=0.6088
 Female 9 2(22%) 
Baseline HCV level 
 < 1 Meq/ml 13 7(54%) 
                                                       p=0.0059
 al Meq/ml 15 1(7%) 
IRF-1/IRF-2 ratio 
 <2.5 15 7(47%) 
                                                          p=0.0228
 a2.5 13 1(8%) 
Combination of HCV level 
and IRF-1/IRF-2 ratio 
 Both HCV < 1Meq/ml 7 6(86%) 
  and ratio < 2.5 p=0.0001 
 Others 21 2(10%)
       The definition of complete response was mentioned in Methods. The statistical 
analysis was carried out using the chi-square test.
Discussion
 In this study, the expression ratio of IRF-1 to IRF-2 
mRNA in the liver tissue in patients with chronic 
hepatitis C was significantly higher than that in con-
trol. In the IFN system, IRF-1 and IRF-2 regulate both 
IFN genes and IFN-inducible genes coordinately". 
IFNs bind to their receptors and stimulate IRF-1 gene 
expression. IRF-1 activates expression of IFN genes, re-
sulting in further induction of IRF-1. However, since 
the 5'-upstream regulatory sequence of the IRF-2 gene 
contains the IRF response element, IRF-1 overexpression 
subsequently induces IRF-2 expression which represses 
IRF-1 function by competing in the same cis-acting ele-
ment. In addition, the half life of IRF-1 mRNA is much 
shorter than that of IRF-2 mRNA". Accordingly, IRF-2 
expression is always predominant over IRF-1 expres-
sion in quiescent cells without stimulation, while ongo-
ing stimulation leads to the increased expression ratio 
of IRF-1 to IRF-2. Thus, our result seems to indicate 
that the IFN-mediated pathway in the liver tissue is 
steadily activated in patients chronically infected by 
HCV. The expression ratios of IRF-1 to IRF-2 mRNA in
the liver tissue did not correlate with the serum levels 
of HCV-RNA in the 54 patients chronically infected by 
HCV. The lack of correlation is difficult to explain 
given our current understanding of the antiviral states 
induced by IFN. One possible explanation is that there 
are mechanisms underlying IFN-induced antiviral ac-
tivities independent of IRF-114-161, although the activa-
tion of IFN-mediated pathways is manifested by the 
increased expression ratio of IRF-1 to IRF-2. Consistent 
with this, several investigators reported that IRF-1 was 
necessary for the antiviral actions of IFN against some 
viruses, but did not affect replication of other types of 
viruses"". In addition, current studies have shown that 
the variants of HCV-1b containing mutations in the 
NS5A region are susceptible to IFNS•6>. The wild-type 
of the NS5A product can bind to the IFN-inducible 
double-stranded RNA-dependent protein kinase, a po-
tent inhibitor of viral replication"', and suppresses its 
function"'. In contrast, the mutant viral gene products 
cannot, resulting in sensitizing the variant viurses to 
IFN19>. This may, in part, account for the lack of corre-
lation between the activation of the IFN-mediated 
pathway and the serum level of HCV-RNA, although 
the HCV-RNA sequences were not determined in this 
study. 
  By the analysis of factors involved in response to 
IFN in patients with chronic hepatitis C, the relatively 
lower level of viremia prior to IFN treatment was as-
sociated with complete response to IFN in this study. 
Similar results were described previously, where IFN 
treatment succeeded in viral eradication in 50-60% of 
patients with the baseline HCV-RNA levels of less 
than l Meq/ml, but in only approximately 10% of pa-
tients with relatively higher levels of viremia1-4>. With 
respect to relationship between the expression ratio of 
IRF-1 to IRF-2 mRNA in the liver tissue and response 
to IFN, complete response was observed more fre-
quently in patients who had the ratios of less than the 
cutoff value corresponding to the mean value in the 
54 patients chronically infected by HCV, compared 
with those who did not. Moreover, 6 (87%) of 7 pa-
tients who had both the low level of viremia and the 
expression ratio of less than the cutoff value resulted 
in complete response, in contrast to only 2 (10%) of 21 
patients who did not. It is, therefore, possible that the 
measurement of the expression ratio of IRF-1 to IRF-2 
mRNA in the liver tissue, particularly combined with 
the baseline serum level of HCV-RNA, serves as a pre-
dictive marker for response to IFN in patients chroni-
cally infected by HCV. 
  In summary, our results suggest that the activation 
of the IFN-mediated pathway manifested by the in-
creased expression ratio of IRF-1 to IRF-2 mRNA in
the liver tissue occurs in a large portion of patients 
chronically infected by HCV, and that its preceded 
overactivation is related with attenuated response to 
IFN in these patients. The host-defense mechanisms 
against HCV are unlikely to result from a single-step 
event, but rather represent a complex process involv-
ing IFN system"-22'. Given these conditions, viral gene 
products or altered products caused by viral gene muta-
tions are considered to modify the IFN-induced antiviral 
activities, although the IFN-mediated activation path-
ways play a crucial role in viral clearance.
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